FindTrial
Sign In

Treatment of coronary heart disease in rheumatoid arthritis with leflunomide combined with ligustrazine in clinical research

Treatment of coronary heart disease in rheumatoid arthritis with leflunomide combined with ligustrazine in clinical research

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-12001859
Enrollment
Unknown
Registered
2012-01-04
Start date
2012-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary heart disease in rheumatoid arthritis

Interventions

1:leflunomide combined with ligustrazine
2:leflunomide combined with placebo

Sponsors

Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. coronary artery disease in rheumatoid arthritis; 2. the subjects or their families (Guardian ) signed consent to participate in the study; 3. at the age of 18 ~ 65 years old.

Exclusion criteria

Exclusion criteria: Does not comply with the above.

Design outcomes

Primary

MeasureTime frame
Routine blood test;Biochemical examination;Immunohistochemical examination;Metabolomics check;—

Countries

China

Contacts

Public ContactAiping Lu
lap64067611@126.com+86 010 64014411

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026